The DESTINY-Lung02 trial, which builds on the findings of the DESTINY-Lung01 trial, explored trastuzumab deruxtecan’s efficacy in HER2-mutant NSCLC patients. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.